Posters

Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX

Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial

Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial

COMPOSE® Phase 1/2, dose-escalation Cohort 7 design: safety of pegtibatinase in children aged ≥5-<12 years with classical homocystinuria (HCU)

Pegtibatinase, an Investigational Enzyme Replacement Therapy for Classical Homocystinuria (HCU): Design of the HARMONY and ENSEMBLE Phase 3 Studies

Kidney Outcomes and the Effect of Proteinuria in Alport Syndrome: A Longitudinal Analysis Using Data From the National Registry of Rare Kidney Diseases (RaDaR)

Population modelling depicts the mutational burden of NPHS2 (podocin) nephropathy and reveals an undiagnosed adult-onset genetic cohort

Sparsentan Reversibly Decreases Mesangial IgA Deposition in gddY Mice: A Possible Role for Mesangial-Cell -Surface Autoantigen Expression

Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)

Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT

Improving Proteinuria With Sparsentan (SPAR) in Patients With IgA Nephropathy (IgAN): A Case Series 

Patient-Reported Outcomes in Rare Kidney Disease Clinical Trials: Sparsentan Versus Irbesartan